GO Term | Evidence Code | PMID |
---|---|---|
positive regulation of MAP kinase activity | ||
adaptive immune response |
|
|
sphingosine-1-phosphate receptor signaling pathway | ||
G protein-coupled receptor signaling pathway | ||
cell migration |
GO Term | Evidence Code | PMID |
---|---|---|
kinase activity | ||
ephrin receptor binding | ||
1-phosphatidylinositol-3-kinase activity | ||
protein serine/threonine kinase activity | ||
protein serine kinase activity |
DO ID | Disease Name | Source |
---|---|---|
DOID:12306 | vitiligo | |
DOID:12328 | marasmus | |
DOID:12336 | male infertility | |
DOID:12351 | alcoholic hepatitis | |
DOID:12359 | endocrine exophthalmos | |
DOID:12361 | Graves' disease | |
DOID:12388 | neurohypophyseal diabetes insipidus | |
DOID:1240 | leukemia | |
DOID:12466 | secondary hyperparathyroidism | |
DOID:12603 | acute leukemia |
HPO ID | HPO Term |
---|---|
HP:0002720 | Decreased circulating IgA level |
HP:0002850 | Decreased circulating total IgM |
HP:0002851 | Elevated proportion of CD4-negative, CD8-negative, alpha-beta regulatory T cells |
HP:0003281 | Increased circulating ferritin concentration |
HP:0003621 | Juvenile onset |
HP:0003651 | Foam cells |
HP:0004313 | Decreased circulating antibody level |
HP:0004315 | Decreased circulating IgG level |
HP:0004387 | Enterocolitis |
HP:0005415 | Decreased proportion of CD8-positive T cells |
Disease ID | Disease Name |
---|---|
OMIM:619802 |
|
Species | Gene ID | Alliance of Genome Resources | Orthologous MAtrix |
---|---|---|---|
113436774 | PSETE01002 | ||
103813517 | SERCA06309 | ||
100078046 | ORNAN05315 | ||
100925455 | SARHA13743 | ||
103118136 | ERIEU07700 | ||
100394268 | CALJA43660 | ||
105583147 | CERAT13725 | ||
698857 | MACMU32743 | ||
105475319 | MACNE00055 | ||
101018542 | PAPAN30844 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024